Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

West Pharmaceutical Services (WST)

West Pharmaceutical Services (WST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,119,458
  • Shares Outstanding, K 73,841
  • Annual Sales, $ 1,840 M
  • Annual Income, $ 241,700 K
  • 60-Month Beta 1.17
  • Price/Sales 11.04
  • Price/Cash Flow 58.50
  • Price/Book 12.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.01
  • Number of Estimates 3
  • High Estimate 1.02
  • Low Estimate 1.00
  • Prior Year 0.79
  • Growth Rate Est. (year over year) +27.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
233.52 +16.68%
on 07/15/20
279.54 -2.53%
on 08/03/20
+39.19 (+16.80%)
since 07/14/20
3-Month
195.22 +39.57%
on 05/27/20
279.54 -2.53%
on 08/03/20
+62.12 (+29.53%)
since 05/14/20
52-Week
124.53 +118.80%
on 03/23/20
279.54 -2.53%
on 08/03/20
+130.12 (+91.41%)
since 08/14/19

Most Recent Stories

More News
Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?

Is (WST) Outperforming Other Medical Stocks This Year?

WST : 272.47 (-0.98%)
Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

PKI : 118.25 (-1.46%)
MYGN : 12.66 (-5.38%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
Here's Why You Should Hold on to Stryker (SYK) Stock Now

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

SYK : 188.37 (-1.36%)
PKI : 118.25 (-1.46%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
5 Top-Ranked Stocks Driving ETF as S&P 500 Nears New Highs

Though most stocks in the fund's portfolio are in the green this year, we have highlighted five that are leading the way in the ETF and have a Zacks Rank #2, suggesting their continued outperformance.

REGN : 612.57 (+0.28%)
CDNS : 108.00 (-0.61%)
SPY : 336.84 (unch)
WST : 272.47 (-0.98%)
ROL : 54.73 (-0.49%)
PYPL : 191.46 (-0.83%)
Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.

PKI : 118.25 (-1.46%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
CHNG : 12.81 (unch)
National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat

Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.

HOLX : 66.81 (-1.92%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
EYE : 35.72 (-0.70%)
Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

PKI : 118.25 (-1.46%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
GKOS : 41.92 (-1.23%)
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

HOLX : 66.81 (-1.92%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
SYNH : 60.78 (-3.77%)
Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

HOLX : 66.81 (-1.92%)
IART : 51.25 (-0.91%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.

HOLX : 66.81 (-1.92%)
TMO : 413.76 (-0.68%)
WST : 272.47 (-0.98%)
PODD : 202.13 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade WST with:

Business Summary

West Pharmaceutical Services, Inc. is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines...

See More

Key Turning Points

2nd Resistance Point 278.91
1st Resistance Point 275.69
Last Price 272.47
1st Support Level 270.01
2nd Support Level 267.55

See More

52-Week High 279.54
Last Price 272.47
Fibonacci 61.8% 220.33
Fibonacci 50% 202.04
Fibonacci 38.2% 183.74
52-Week Low 124.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar